SteelPeak Wealth LLC cut its stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 5.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 538,176 shares of the company's stock after selling 30,000 shares during the period. SteelPeak Wealth LLC owned approximately 0.96% of Astrana Health worth $13,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue boosted its stake in Astrana Health by 7.3% during the second quarter. State of Alaska Department of Revenue now owns 24,723 shares of the company's stock worth $614,000 after buying an additional 1,690 shares during the last quarter. Strs Ohio acquired a new position in shares of Astrana Health during the 1st quarter valued at about $332,000. Intech Investment Management LLC grew its holdings in shares of Astrana Health by 5.8% in the first quarter. Intech Investment Management LLC now owns 44,586 shares of the company's stock valued at $1,383,000 after purchasing an additional 2,462 shares during the period. Jones Financial Companies Lllp increased its position in Astrana Health by 4,365.2% during the first quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company's stock worth $346,000 after purchasing an additional 10,913 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Astrana Health by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company's stock worth $799,000 after purchasing an additional 1,263 shares during the period. Institutional investors and hedge funds own 52.77% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on ASTH shares. Zacks Research cut shares of Astrana Health from a "strong-buy" rating to a "strong sell" rating in a research note on Monday, September 1st. Weiss Ratings reissued a "hold (c-)" rating on shares of Astrana Health in a research note on Saturday, September 27th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $50.50.
Check Out Our Latest Analysis on ASTH
Astrana Health Stock Performance
Shares of ASTH stock opened at $28.87 on Tuesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.59 and a current ratio of 1.59. The firm has a market cap of $1.62 billion, a P/E ratio of 56.61, a P/E/G ratio of 0.71 and a beta of 0.80. The firm's 50 day moving average price is $28.40 and its 200-day moving average price is $27.84. Astrana Health, Inc. has a one year low of $21.20 and a one year high of $63.20.
Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.36 by ($0.17). Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.The firm had revenue of $654.81 million for the quarter, compared to analyst estimates of $639.13 million. During the same quarter last year, the company earned $0.40 earnings per share. The firm's revenue for the quarter was up 34.7% on a year-over-year basis. Astrana Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Company Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
